Franco Kraiselburd

Franco Kraiselburd is a biomedical engineer, inventor, and entrepreneur dedicated to advancing and scaling regenerative medicine. He earned his B.S. in Biomedical Engineering from Case Western Reserve University in 2024. Recognized as a 2024 MIT Innovator Under 35 and awarded the MIT LATAM Pioneer of the Year 2024 award, Franco raised $1 million in non-dilutive grants before graduating college, gaining traction from prestigious organizations such as NSF, NIH, and other internationally recognized research organizations.

In 2022, at age 19, he founded Asclepii, a medical-device company developing next-generation medical dressings - Wound Matrixes and Nanosilver Hydrogels - for superior wound bed preparation. As CEO, he has raised more than $3 million of Venture-backed funding, assembled a global network of scientific leaders across seven countries, and secured core intellectual property. Asclepii’s technology has been by the MIT, Forbes, SXSW, and Crain’s Business Magazine.

Prior to Asclepii, Kraiselburd conducted translational research at Case Western’s Skeletal Research Center under the “Father of Mesenchymal Stem Cells” - who founded Osiris Therapeutics (acq. Smith + Nephew, 2019). He also conducted work at the University of São Paulo’s Cell and Molecular Therapy Center, where he developed a bioactive calcium-alginate hydrogel that reached pre-clinical trials at the age of 14. His work has contributed to major federal grants, including a $47.5 million ARPA-H award for the manufacturing of artificial joints, and has been presented at the Biomedical Engineering Society annual meeting.